Maplebear CART 深 沪
等待开盘 09-02 09:30:00 美东时间
50.05
-0.470
-0.93%
华盛通- 最 高50.695
- 今 开49.90
- 成交量 257.08万股
- 最 低 49.09
- 昨 收 50.52
- 总市值 115.87亿
- 52周最高 52.05
- 市盈率 静 31.31
- 换手率 1.11%
- 52周最低 32.73
- 委 比 46.12%
- 总股本 2.32亿
- 历史最高 53.50
- 量 比 0.99
- 振 幅 3.18%
- 历史最低 22.13
- 每 手 1
- 风险率 4.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
今天 14:07
Rosenblatt Initiates Coverage On Maplebear with Neutral Rating, Announces Price Target of $55
Rosenblatt analyst Scott Devitt initiates coverage on Maplebear (NASDAQ:CART) with a Neutral rating and announces Price Target of $55.
09-01 20:09
Instacart and Petsense by Tractor Supply Launch Exclusive Same-Day Delivery Partnership
The specialty pet retailer brings delivery in as fast as an hour to pet lovers nationwide with no markups SAN FRANCISCO and BRENTWOOD, Tenn., Aug. 25, 2026 /PRNewswire/ -- Instacart (Nasdaq:...
08-25 21:00
期权扫描 | 英伟达七连跌后反弹在望？资金押注绩后股价重回230美元；Meta看涨期权占比逾七成
英伟达七连跌后反弹在望？资金押注绩后股价重回230美元；AI新模型呼之欲出，Meta看涨期权占比逾七成；Strategy升势放缓，期权成交提前降温>>
08-25 16:32
FTC to crack down on retailers using 'personalized pricing'
The Federal Trade Commission announced a new enforcement bulletin warning retailers that the practice of using consumer data to determine a group’s tolerance to higher prices will now violate consumer...
08-20 01:28
Instacart Expands On-Demand Retail Delivery with Foot Locker, Kids Foot Locker, and Champs Sports
New partnership offers customers on-demand, fast delivery of the latest footwear styles, apparel and accessories SAN FRANCISCO and NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Instacart (Nasdaq: ...
08-19 21:00
Maplebear Inc. (Instacart) Delivers Profitable Growth
Maplebear Inc. (($CART)) has held its Q2 earnings call. Read on for the main hi...
08-12 08:24
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
